Clinical application of the Biotrack 516 system for determination of theophylline by a turbidimetric latex agglutination inhibition reaction

Yoshimi Tsunekawa, Takaaki Hasegawa, Masayuki Nadai, Ken Ichi Yamaki, Kenzo Takagi, Toshitaka Nabeshima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Several automated analytical systems for therapeutic drug monitoring (TDM) have been developed. In the present study, theophylline concentration in plasma was measured by the Biotrack 516 system for theophylline, a newly developed automated system based on the turbidimetric latex agglutination inhibition reaction, using whole blood samples obtained from 35 asthmatic patients receiving chronic theophylline therapy. The data were compared with those obtained by high-performance liquid chromatography (HPLC) and fluorescence polarization immunoassay (FPIA). Within-day and between-day precisions for the Biotrack system using blood samples obtained from nine patients ranged from 4.1 to 5.8% and from 2.0 to 6.2%, respectively. Comparison of this system with HPLC and FPIA methods indicated good correlation coefficients of >0.960, while the respective slope and intercept did not differ from unity and zero. No cross-reactivity of this system with the main metabolites of theophylline and caffeine was observed, thus indicating that the antibodies possess specificity for theophylline. These findings suggest that the Biotrack-516 system is a method that enjoys both accuracy and precision to the same degree as established methods and hence will prove useful in the routine monitoring of plasma theophylline concentrations.

Original languageEnglish
Pages (from-to)86-91
Number of pages6
JournalTherapeutic Drug Monitoring
Volume18
Issue number1
DOIs
Publication statusPublished - 06-02-1996
Externally publishedYes

Fingerprint

Agglutination
Latex
Theophylline
Fluorescence Polarization Immunoassay
High performance liquid chromatography
Blood
Fluorescence
High Pressure Liquid Chromatography
Polarization
Plasmas
Antibody Specificity
Monitoring
Drug Monitoring
Metabolites
Caffeine
Antibodies
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Health, Toxicology and Mutagenesis
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Pharmacology
  • Toxicology

Cite this

Tsunekawa, Yoshimi ; Hasegawa, Takaaki ; Nadai, Masayuki ; Yamaki, Ken Ichi ; Takagi, Kenzo ; Nabeshima, Toshitaka. / Clinical application of the Biotrack 516 system for determination of theophylline by a turbidimetric latex agglutination inhibition reaction. In: Therapeutic Drug Monitoring. 1996 ; Vol. 18, No. 1. pp. 86-91.
@article{6cd1b8616dfe4545aeec148b882cd133,
title = "Clinical application of the Biotrack 516 system for determination of theophylline by a turbidimetric latex agglutination inhibition reaction",
abstract = "Several automated analytical systems for therapeutic drug monitoring (TDM) have been developed. In the present study, theophylline concentration in plasma was measured by the Biotrack 516 system for theophylline, a newly developed automated system based on the turbidimetric latex agglutination inhibition reaction, using whole blood samples obtained from 35 asthmatic patients receiving chronic theophylline therapy. The data were compared with those obtained by high-performance liquid chromatography (HPLC) and fluorescence polarization immunoassay (FPIA). Within-day and between-day precisions for the Biotrack system using blood samples obtained from nine patients ranged from 4.1 to 5.8{\%} and from 2.0 to 6.2{\%}, respectively. Comparison of this system with HPLC and FPIA methods indicated good correlation coefficients of >0.960, while the respective slope and intercept did not differ from unity and zero. No cross-reactivity of this system with the main metabolites of theophylline and caffeine was observed, thus indicating that the antibodies possess specificity for theophylline. These findings suggest that the Biotrack-516 system is a method that enjoys both accuracy and precision to the same degree as established methods and hence will prove useful in the routine monitoring of plasma theophylline concentrations.",
author = "Yoshimi Tsunekawa and Takaaki Hasegawa and Masayuki Nadai and Yamaki, {Ken Ichi} and Kenzo Takagi and Toshitaka Nabeshima",
year = "1996",
month = "2",
day = "6",
doi = "10.1097/00007691-199602000-00014",
language = "English",
volume = "18",
pages = "86--91",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Clinical application of the Biotrack 516 system for determination of theophylline by a turbidimetric latex agglutination inhibition reaction. / Tsunekawa, Yoshimi; Hasegawa, Takaaki; Nadai, Masayuki; Yamaki, Ken Ichi; Takagi, Kenzo; Nabeshima, Toshitaka.

In: Therapeutic Drug Monitoring, Vol. 18, No. 1, 06.02.1996, p. 86-91.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical application of the Biotrack 516 system for determination of theophylline by a turbidimetric latex agglutination inhibition reaction

AU - Tsunekawa, Yoshimi

AU - Hasegawa, Takaaki

AU - Nadai, Masayuki

AU - Yamaki, Ken Ichi

AU - Takagi, Kenzo

AU - Nabeshima, Toshitaka

PY - 1996/2/6

Y1 - 1996/2/6

N2 - Several automated analytical systems for therapeutic drug monitoring (TDM) have been developed. In the present study, theophylline concentration in plasma was measured by the Biotrack 516 system for theophylline, a newly developed automated system based on the turbidimetric latex agglutination inhibition reaction, using whole blood samples obtained from 35 asthmatic patients receiving chronic theophylline therapy. The data were compared with those obtained by high-performance liquid chromatography (HPLC) and fluorescence polarization immunoassay (FPIA). Within-day and between-day precisions for the Biotrack system using blood samples obtained from nine patients ranged from 4.1 to 5.8% and from 2.0 to 6.2%, respectively. Comparison of this system with HPLC and FPIA methods indicated good correlation coefficients of >0.960, while the respective slope and intercept did not differ from unity and zero. No cross-reactivity of this system with the main metabolites of theophylline and caffeine was observed, thus indicating that the antibodies possess specificity for theophylline. These findings suggest that the Biotrack-516 system is a method that enjoys both accuracy and precision to the same degree as established methods and hence will prove useful in the routine monitoring of plasma theophylline concentrations.

AB - Several automated analytical systems for therapeutic drug monitoring (TDM) have been developed. In the present study, theophylline concentration in plasma was measured by the Biotrack 516 system for theophylline, a newly developed automated system based on the turbidimetric latex agglutination inhibition reaction, using whole blood samples obtained from 35 asthmatic patients receiving chronic theophylline therapy. The data were compared with those obtained by high-performance liquid chromatography (HPLC) and fluorescence polarization immunoassay (FPIA). Within-day and between-day precisions for the Biotrack system using blood samples obtained from nine patients ranged from 4.1 to 5.8% and from 2.0 to 6.2%, respectively. Comparison of this system with HPLC and FPIA methods indicated good correlation coefficients of >0.960, while the respective slope and intercept did not differ from unity and zero. No cross-reactivity of this system with the main metabolites of theophylline and caffeine was observed, thus indicating that the antibodies possess specificity for theophylline. These findings suggest that the Biotrack-516 system is a method that enjoys both accuracy and precision to the same degree as established methods and hence will prove useful in the routine monitoring of plasma theophylline concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0030059998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030059998&partnerID=8YFLogxK

U2 - 10.1097/00007691-199602000-00014

DO - 10.1097/00007691-199602000-00014

M3 - Article

VL - 18

SP - 86

EP - 91

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 1

ER -